Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm) - Europe/Hamburg
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
- Nour Fahmi, PhD - Director, Chemistry, Eli Lilly and Company
GLP-1–based therapies have transformed the treatment of metabolic diseases, evolving from first-generation peptides such as liraglutide to long-acting analogues like semaglutide. This talk will explore the scientific and technological journey behind these advances, with a focus on extending dosing intervals toward even more infrequent administration, as well as enabling oral peptide delivery.
- Jacob Challand Kofoed, PhD - Scientific Director, Peptide Research, Novo
Retatrutide, a novel GIP, GLP-1, and glucagon receptor agonist, has demonstrated efficacy and an acceptable safety profile to date across the Phase 3 TRIUMPH program (obesity, obstructive sleep apnea, and osteoarthritic knee pain) and TRANSCEND-T2D program (type 2 diabetes). This keynote delivers an in-depth CMC perspective on the manufacturing innovation enabling global-scale supply: the convergent liquid-phase peptide synthesis (LPPS) platform — encompassing fragment strategy, protecting group design, and process intensification — and the ICH Q11-grounded starting material justification framework. Together, these advances yield a commercial process of exceptional efficiency, dramatically reduced PMI, and new benchmarks for sustainable large-molecule manufacturing.
- Michael Kopach, PhD - Associate Vice President, Synthetic Molecule Design and Development, Eli Lilly and Company
- Claudia Höbartner, Ph.D. - Professor of Organic Chemistry, University of Würzburg
This presentation highlights the clinical validation of the Axiomer ADAR-mediated RNA editing platform, demonstrating favorable safety, dose-dependent target engagement, and good translatability from preclinical in a first-in-human study in healthy volunteers. It also shows AI-enabled advances in the discovery of next-generation editing oligonucleotides with enhanced potency and durability, supporting the platform's potential for treating liver and CNS diseases.
- Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics

